Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer

Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer

Abstract Acquired resistance to hormonal therapy, particularly enzalutamide (ENZ), remains a significant obstacle in the treatment of advanced bone metastatic prostate cancer. Here, it is demonstrated that under ENZ treatment, osteoblasts in the bone microenvironment secrete increased levels of extr...

Full description

Saved in:
Bibliographic Details
Main Authors: Xinwen Wang, Min Wang, Qijun Lin, Lixin He, Baolin Zhang, Xin Chen, Guanhong Chen, Hong Du, Chuandong Lang, Xinsheng Peng, Yuhu Dai
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Advanced Science
Subjects:
ECM1
ENO1
enzalutamide resistance
osteoblast
prostate cancer
Online Access:https://doi.org/10.1002/advs.202407662
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/advs.202407662

Similar Items